Impairment of Filgrastim-Induced Stem Cell Mobilization after Prior Lenalidomide in Patients with Multiple Myeloma

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 6, 2009, Pages 718-723

  Popat, Uday ^a   Saliba, Rima ^a   Thandi, Rupinderjit ^a   Hosing, Chitra ^a   Qazilbash, Muzaffar ^a   Anderlini, Paolo ^a   Shpall, Elizabeth ^a   McMannis, John ^a   Körbling, Martin ^a   Alousi, Amin ^a   Andersson, Borje ^a   Nieto, Yago ^a   Kebriaei, Partow ^a   Khouri, Issa ^a   de Lima, Marcos ^a   Weber, Donna ^a   Thomas, Sheeba ^a   Wang, Michael ^a   Jones, Roy ^a   Champlin, Richard ^a   Giralt, Sergio ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Autotransplant; Myeloma; Stem cell mobilization

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LENALIDOMIDE; PLERIXAFOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN CELL; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PREDICTION; RETREATMENT; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION; TREATMENT OUTCOME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FEMALE; FILGRASTIM; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; IFOSFAMIDE; LEUKAPHERESIS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; RISK FACTORS; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT FAILURE; VINCRISTINE;

EID: 67349243088     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.02.011     Document Type: Article

References (29)

1. Kyle R.A., and Rajkumar S.V. Multiple myeloma. Blood 111 (2008) 2962-2972
2. Reece D.E. Management of multiple myeloma: the changing landscape. Blood Rev 21 (2007) 301-314
3. Anagnostopoulos A., Weber D., Rankin K., Delasalle K., and Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 121 (2003) 768-771
4. Dimopoulos M., Spencer A., Attal M., et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357 (2007) 2123-2132
5. Dimopoulos M.A., Anagnostopoulos A., and Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol 21 (2003) 4444-4454
6. Jagannath S., Barlogie B., Berenson J., et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127 (2004) 165-172
7. Lee C.K., Barlogie B., Munshi N., et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 21 (2003) 2732-2739
8. Palumbo A., Ambrosini M.T., Benevolo G., et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 109 (2007) 2767-2772
9. Richardson P.G., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348 (2003) 2609-2617
10. Richardson P.G., Blood E., Mitsiades C.S., et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108 (2006) 3458-3464
11. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352 (2005) 2487-2498
12. Singhal S., Mehta J., Desikan R., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341 (1999) 1565-1571
13. Weber D.M., Chen C., Niesvizky R., et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357 (2007) 2133-2142
14. Jagannath S., Durie B.G., Wolf J., et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 129 (2005) 776-783
15. Oakervee H.E., Popat R., Curry N., et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 129 (2005) 755-762
16. Rajkumar S.V., Blood E., Vesole D., Fonseca R., and Greipp P.R. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24 (2006) 431-436
17. Rajkumar S.V., Hayman S.R., Lacy M.Q., et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106 (2005) 4050-4053
18. Weber D., Rankin K., Gavino M., Delasalle K., and Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21 (2003) 16-19
19. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335 (1996) 91-97
20. Barlogie B., Jagannath S., Vesole D.H., et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89 (1997) 789-793
21. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348 (2003) 1875-1883
22. Palumbo A., Bringhen S., Petrucci M.T., et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 104 (2004) 3052-3057
23. Bensinger W., Appelbaum F., Rowley S., et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 13 (1995) 2547-2555
24. Cottler-Fox M.H., Lapidot T., Petit I., et al. Stem cell mobilization. Hematology Am Soc Hematol Educ Program (2003) 419-437
25. Morris C.L., Siegel E., Barlogie B., et al. Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 120 (2003) 413-423
26. Boccadoro M., Palumbo A., Bringhen S., et al. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica 87 (2002) 846-850
27. Kumar S., Dispenzieri A., Lacy M.Q., et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 21 (2007) 2035-2042
28. Mazumder A., Kaufman J., Niesvizky R., Lonial S., Vesole D., and Jagannath S. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia 22 (2007) 1280-1281
29. Paripati H., Stewart A.K., Cabou S., et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 22 (2008) 1281-1284